Cytokinetics to Hold Annual Meeting of Stockholders
May 11 2016 - 4:00PM
Cytokinetics, Inc. (Nasdaq:CYTK) announced today that its Annual
Meeting of Stockholders will be held on Wednesday, May 18, 2016 at
10:30 AM Pacific Time at the Embassy Suites Hotel, located at 250
Gateway Boulevard in South San Francisco, CA. Robert I. Blum,
President and Chief Executive Officer, is scheduled to present an
overview of Cytokinetics’ performance.
Interested parties may access the live webcast
of this presentation by visiting the Investors & Media section
of Cytokinetics’ website at www.cytokinetics.com. The live audio of
the conference call can also be accessed by telephone by dialing
either (866) 999-CYTK (2985) (United States and Canada) or (706)
679-3078 (international) and typing in the passcode 87061652.
An archived replay of the webcast will be
available via Cytokinetics' website until May 25, 2016. The replay
will also be available via telephone by dialing (855) 859-2056
(United States and Canada) or (404) 537-3406 (international) and
typing in the passcode 87061652 from May 18, 2016 at 1:30 PM
Pacific Time until May 25, 2016.
About Cytokinetics
Cytokinetics is a late-stage
biopharmaceutical company focused on discovering, developing and
commercializing first-in-class muscle activators as potential
treatments for debilitating diseases in which muscle performance is
compromised and/or declining. With an unmatched understanding of
muscle biology and the mechanics of muscle performance, the company
is developing small molecule drug candidates specifically
engineered to increase muscle function and contractility.
Cytokinetics’ lead drug candidate is tirasemtiv, a fast
skeletal muscle activator, for the potential treatment of
ALS. Tirasemtiv has been granted orphan drug
designation and fast track status by the U.S. Food and Drug
Administration and orphan medicinal product designation by
the European Medicines Agency for the potential treatment
of ALS. Cytokinetics holds the exclusive right to develop and
commercialize tirasemtiv. Cytokinetics is
collaborating with Amgen Inc. to develop omecamtiv
mecarbil, a novel cardiac muscle activator, for the potential
treatment of heart failure. Cytokinetics is collaborating
with Astellas Pharma Inc. to develop CK-2127107, a fast
skeletal muscle activator, for the potential treatment of spinal
muscular atrophy. Amgen holds an exclusive license
worldwide to develop and commercialize omecamtiv mecarbil and
Astellas holds an exclusive license worldwide to develop and
commercialize CK-2127107. Both licenses are subject to
Cytokinetics’ specified development and commercialization
participation rights. For additional information
about Cytokinetics, visit www.cytokinetics.com.
This press release contains forward-looking
statements for purposes of the Private Securities Litigation Reform
Act of 1995 (the “Act”). Cytokinetics disclaims any intent or
obligation to update these forward-looking statements, and claims
the protection of the Act’s safe harbor for forward-looking
statements. Examples of such statements include, but are not
limited to, statements relating to planned presentations, and the
properties and potential benefits of Cytokinetics’ drug candidates
and potential drug candidates. Such statements are based on
management’s current expectations, but actual results may differ
materially due to various risks and uncertainties, including, but
not limited to, potential difficulties or delays in the
development, testing, regulatory approval and production of
Cytokinetics' drug candidates and potential drug candidates that
could slow or prevent clinical development or product approval,
including risks that current and past results of clinical trials or
preclinical studies may not be indicative of future clinical trials
results and that Cytokinetics' drug candidates and potential drug
candidates may have unexpected adverse side effects or inadequate
therapeutic efficacy. For further information regarding these and
other risks related to Cytokinetics’ business, investors should
consult Cytokinetics’ filings with the Securities and Exchange
Commission.
Contact:
Cytokinetics
Diane Weiser
Vice President, Corporate Communications, Investor Relations
(650) 624-3060
Cytokinetics (NASDAQ:CYTK)
Historical Stock Chart
From Mar 2024 to Apr 2024
Cytokinetics (NASDAQ:CYTK)
Historical Stock Chart
From Apr 2023 to Apr 2024